MARKET

AGRX

AGRX

Agile
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.030
0.000
0.00%
Closed 16:00 09/23 EDT
OPEN
1.050
PREV CLOSE
1.030
HIGH
1.050
LOW
1.020
VOLUME
403.27K
TURNOVER
--
52 WEEK HIGH
3.770
52 WEEK LOW
0.9302
MARKET CAP
95.79M
P/E (TTM)
-1.3316
1D
5D
1M
3M
1Y
5Y
HC Wainwright & Co. Maintains Buy on Agile Therapeutics, Lowers Price Target to $3.5
HC Wainwright & Co. analyst Oren Livnat maintains Agile Therapeutics (NASDAQ:AGRX) with a Buy and lowers the price target from $7 to $3.5.
Benzinga · 09/13 10:49
--HC Wainwright Adjusts Agile Therapeutics PT to $3.50 From $7, Maintains Buy Rating
MT Newswires · 09/13 09:34
BRIEF-Agile Therapeutics Estimates Net Sales In Q3 Of 2021 Will Be In Range Of $1.4 Million To $1.6 Million
reuters.com · 09/10 21:33
Agile Therapeutics to Participate in Upcoming Investor Conferences
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that management will present and participate at the following virtual investor conferences during the month of September 2021.
GlobeNewswire · 09/07 11:30
BRIEF-Agile Therapeutics Partners With Telehealth Service, Pandia Health, To Increase Women’S Access To Twirla® Transdermal System
reuters.com · 08/20 11:37
Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
Pandia Health is a doctor founded and led telehealth company, offering online prescriptions and free delivery designed to make it easier for women to access birth control options that meet their needsPartnership represents first telehealth alliance for Agi...
GlobeNewswire · 08/20 11:30
Agile Therapeutics Working With Pandia Health to Open Telehealth Service Channel for Birth Control Patch; Shares Rise Pre-Bell
MT Newswires · 08/20 07:59
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGRX. Analyze the recent business situations of Agile through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGRX stock price target is 3.833 with a high estimate of 4.000 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 103
Institutional Holdings: 43.24M
% Owned: 46.49%
Shares Outstanding: 93.00M
TypeInstitutionsShares
Increased
14
2.03M
New
21
2.43M
Decreased
23
7.04M
Sold Out
27
1.42M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chairman/Chief Executive Officer/Director
Alfred Altomari
Chief Financial Officer/Senior Vice President
Dennis Reilly
Senior Vice President/General Counsel/Secretary
Geoffrey Gilmore
Senior Vice President
Robert Conway
Senior Vice President
Paul Korner
Lead Director/Independent Director
Seth Fischer
Independent Director
Sharon Barbari
Independent Director
Sandra Carson
Independent Director
John Hubbard
Independent Director
Ajit Shetty
Independent Director
James Tursi
No Data
About AGRX
Agile Therapeutics, Inc. is a women’s healthcare company. The Company’s approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla uses its transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability, which may help support compliance. Its product pipeline consists of two types of product candidates: Twirla line extensions and other transdermal contraceptive product candidates. These potential product candidates are designed to address market needs of additional non-daily contraceptive options. Its Twirla line extensions include AG200-15 Extended Regimen (ER), AG200-15 SmP, AG200-15 ER SmP, and AG890, a P-only contraceptive patch.

Webull offers kinds of Agile Therapeutics Inc stock information, including NASDAQ:AGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGRX stock methods without spending real money on the virtual paper trading platform.